Conventional Medical Therapy in IBD

Mesalamine is NOT a systemic anti-inflammatory drug — it is a topical agent that happens to be delivered orally. The formulation determines WHERE the drug reaches. A patient on a pH-dependent oral preparation with terminal ileal Crohn's gets no delivery to inflamed tissue; a UC patient with extensive disease on topical-only therapy gets inadequate coverage. Match the delivery profile to the disease extent.

Once-daily 5-ASA dosing is therapeutically equivalent to divided dosing and significantly improves adherence — in real-world IBD practice, adherence to divided mesalamine regimens is under 50%, whereas once-daily achieves 70-80%. Prescribe once-daily as the default unless there is a specific reason to divide.

The single most impactful intervention you can make in mild-moderate UC is to persuade the patient to actually use their topical therapy. Invest the 5 minutes of clinic time to demonstrate technique with a visual aid and a written script — this changes outcomes more than switching to a biologic for most mild-moderate UC patients.

Mesalamine does not work in Crohn's disease. Despite decades of off-label prescribing, the evidence is consistent: no benefit at any dose, for induction or maintenance. Continuing 5-ASA in a Crohn's patient is effectively delaying effective therapy. When you see a new Crohn's referral on mesalamine alone, stop it and escalate.

A sudden unexplained rise in creatinine in a 5-ASA patient is mesalamine interstitial nephritis until proven otherwise — stop the drug immediately and refer to nephrology. Do not rechallenge.

Write the steroid discontinuation date on the prescription itself. "Prednisolone 40 mg daily, reduce by 10 mg every 7 days, finish on [specific date 6 weeks out]." This one habit — a defined end date — is the single most effective intervention against iatrogenic steroid dependency.

Budesonide-EC (Entocort) is the correct first-line induction for mild-moderate ileocecal Crohn's disease. Do not reach for prednisolone as a reflex — for the ileocecal CD phenotype specifically, budesonide is nearly as effective with a dramatically better toxicity profile. Reserve systemic prednisolone for moderate-severe CD, extensive CD, or steroid-resistant disease.

Any patient receiving their second course of systemic steroids within 12 months, or who has been on prednisolone >10 mg/day for more than 3 months, has failed steroid therapy — escalate to an immunomodulator or biologic at that visit. Continuing steroids is not a plan; it is a delay in escalating to disease-modifying therapy and accumulates irreversible harm.

Never start a steroid course without writing down the exit strategy. "When does this patient come off?" is the question that distinguishes fellows from residents.

In Saudi IBD practice, ALWAYS check both TPMT activity AND NUDT15 genotype before starting thiopurines. TPMT alone misses the most common pharmacogenomic cause of severe thiopurine myelosuppression in Middle Eastern patients. Starting AZA without NUDT15 testing is the #1 preventable cause of severe thiopurine toxicity in our population.

The allopurinol-thiopurine co-therapy is one of the most under-utilized tools in IBD. A patient with subtherapeutic 6-TGN and high 6-MMP ("shunter") who has already been on thiopurines for 3 months without response does not need escalation to a biologic — they need allopurinol 100 mg added with a 75% thiopurine dose reduction. Within 6-8 weeks, 6-TGN levels correct and many of these patients respond clinically.

Thiopurine-induced pancreatitis is idiosyncratic (not dose-related) and permanent — once it has occurred, the drug must not be re-challenged. Distinguish it from gallstone, alcohol, or hypertriglyceridemic pancreatitis in the new thiopurine starter: typical onset is weeks 1-4, lipase >3× ULN, and no other obvious cause.

Structure your thiopurine risk counseling around ABSOLUTE (not relative) risk numbers, and always compare against the absolute benefit of sustained disease control. "Your risk of lymphoma rises from 20 to 50 per 100,000 per year on azathioprine — 30 extra per 100,000. Your risk of disability from untreated IBD flare is several thousand per 100,000 per year." Framed this way, most patients clearly see that the net benefit is favorable.

The allopurinol-thiopurine combination is not a workaround — it is an evidence-based rescue strategy for shunters. Learn it; it will salvage a third of your secondary failures.

For any MTX dose above 15 mg weekly, switch from oral to subcutaneous injection. Oral absorption plateaus around 15 mg and becomes unreliable above that. In Crohn's patients being inducted on 25 mg weekly, oral tablets deliver inadequate and inconsistent exposure — teaching a patient to self-administer a weekly SC injection (similar to the insulin or adalimumab pen) is straightforward and transforms efficacy.

For young Saudi male patients requiring combination immunomodulator + anti-TNF therapy, consider MTX rather than thiopurines — it avoids the HSTCL risk signal that is specific to young men on combination thiopurine + anti-TNF. The efficacy of MTX for anti-drug antibody reduction is comparable, and the lymphoma risk profile is much more favorable in this demographic.

MTX is an ABSOLUTE pregnancy contraindication for both men and women. Before prescribing MTX to any IBD patient of reproductive age, have a documented conversation about contraception and a clear wash-out plan (3 months) if conception is considered. In Saudi practice, frame this around family planning goals and involve partners where culturally appropriate — the outcome of an unplanned pregnancy on MTX can be devastating and is fully preventable.

MTX is the single cheapest and most effective way to reduce biologic immunogenicity. If a patient is on infliximab without MTX and does not have a contraindication, you should be able to defend that choice.

For new mild-moderate UC, the correct first response is NOT steroids or escalation — it is maximal 5-ASA optimization (oral high-dose + topical) with structured adherence support and a documented 8-week review. Fellows who reach for prednisolone at the first visit miss the fact that the majority of patients can achieve steroid-free remission on optimized 5-ASA alone.

On day 3 of IV steroids for ASUC, make a rescue decision. Continuing steroids alone when Oxford criteria are met is not watchful waiting — it is delay, and every day of delay beyond day 3-5 increases colectomy morbidity and mortality. The best ASUC centers commit to a day-3 rescue pathway protocol that is rehearsed and not improvised.

Steroid-dependent Crohn's in a young patient is not managed by rotating steroid courses — it is managed by a biologic-based escalation plan with a structured steroid wean over 8-12 weeks. MTX as the combination immunomodulator (rather than AZA) avoids the HSTCL risk that applies specifically to young men on combination thiopurine + anti-TNF.

The single most important message in IBD pregnancy counseling is: a controlled mother on medications is safer for the baby than an uncontrolled mother off medications. The PIANO registry and subsequent data have clearly established this. In the Saudi context, where family and community pressure sometimes push toward stopping all medications in pregnancy, proactive structured counseling — ideally in a preconception visit with the partner — prevents avoidable harm.

Steroid dependency is not a maintenance plan — it is a failure of strategy. If a patient needs steroids more than once in 12 months, the next conversation is "how do we get you off steroids for good."